Funded Biotechnology Startups in Helsinki
The disclosed funding amounts in Helsinki biotech skew heavily toward one outlier: Solar Foods raised $46M on 2026-06-17, while the next-largest disclosed…
The disclosed funding amounts in Helsinki biotech skew heavily toward one outlier: Solar Foods raised $46M on 2026-06-17, while the next-largest disclosed rounds are $29M (Onego Bio, 2024-04-02) and $21M (Valo Therapeutics, 2025-03-10). That concentration makes most other disclosed checks look small by comparison, including $6M (Nanoform, 2025-06-19) and $5M (Herantis Pharma, 2025-02-06).
The set also clusters temporally around 2024–2025, with three entries in 2025 (Valo Therapeutics on 2025-03-10 for $21M; Herantis Pharma on 2025-02-06 for $5M; Nanoform on 2025-06-19 for $6M) and multiple seed/pre-seed rounds in 2023 (Resistomap $2M on 2023-11-15; Measurlabs $3M on 2023-09-01; Solu $1M on 2023-06-15). Geographically, every listed company is based in Helsinki, Southern Finland, and the 10 rows span 2022-10-04 (NADMED) through 2026-06-17 (Solar Foods).
Most recent rounds
10 shownRelated listings
Frequently asked
Which disclosed round is the outlier in this Helsinki biotech list, and what’s the next tier below it?
Solar Foods’ $46M on 2026-06-17 is the only disclosed round above the rest, with the next-largest disclosed amounts at $29M (Onego Bio on 2024-04-02) and $21M (Valo Therapeutics on 2025-03-10). After that, amounts drop into the single-digit range, including $6M (Nanoform, 2025-06-19) and $5M (Herantis Pharma, 2025-02-06).
Do the most recent entries cluster within the newest time window shown?
Yes. Of the 10 rows, two are in 2026 (Solar Foods on 2026-06-17 for $46M, and none earlier in 2026), and three are in 2025 (Herantis Pharma on 2025-02-06 for $5M; Valo Therapeutics on 2025-03-10 for $21M; Nanoform on 2025-06-19 for $6M). That yields a dense 2025–2026 run compared with the more spread-out 2022–2024 entries.
What stage classifications dominate the disclosed rounds, and how many are “Series Unknown” or undisclosed?
Half of the rows show “Series Unknown” (5 of 10: Solar Foods, Nanoform, Valo Therapeutics, Herantis Pharma, Nexstim). Among the remaining 5, the list includes Seed (Resistomap $2M on 2023-11-15; Nexstim $2M on 2024-06-27 is Series Unknown so not counted here; Measurlabs $3M on 2023-09-01 is Seed; NADMED is Seed but undisclosed on 2022-10-04), plus Pre-Seed (Solu $1M on 2023-06-15) and Series A (Onego Bio $29M on 2024-04-02). There is 1 “undisclosed” amount (NADMED on 2022-10-04).
Are Helsinki locations over-represented, or are there city-level variations to account for?
Every row specifies Helsinki, Southern Finland, Finland for the company’s location, with no alternative Helsinki sub-city entries shown. That makes the geographic pattern uniform across the 10 most recent rounds.
How do the earliest and latest rounds compare in disclosure, and what are the time edges of the dataset shown?
The oldest row shown is 2022-10-04 (NADMED, Seed, undisclosed), while the newest is 2026-06-17 (Solar Foods, Series Unknown, $46M). Within the disclosed amounts, the smallest disclosed check is Solu’s $1M on 2023-06-15 (Pre-Seed), which sits well below the mid-tier rounds like Measurlabs’ $3M (2023-09-01) and Resistomap’s $2M (2023-11-15).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.